FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2919626362> ?p ?o ?g. }

• W2919626362 endingPage "696" @default.
• W2919626362 startingPage "689" @default.
• W2919626362 abstract "Up to 6-months oxaliplatin-containing regimen is now widely accepted as a standard adjuvant chemotherapy for stage III colorectal cancer (CRC). However, oral fluoropyrimidine monotherapy is used for some part of patients, especially in Asian countries including Japan, and its optimal duration is yet to be fully investigated.A total of 1306 patients with curatively-resected stage III CRC were randomly assigned to receive capecitabine (2500 mg/m2/day) for 14 out of 21 days for 6 (n = 654) or 12 (n = 650) months. The primary endpoint was disease-free survival (DFS), and the secondary endpoints were relapse-free survival (RFS), overall survival (OS), and adverse events.The 3- and 5-year DFS were 70.0% and 65.3% in the 6M group and 75.3% and 68.7% in the 12M group, respectively (p = 0.0549, HR = 0.858, 90% CI: 0.732-1.004). The 5-year RFS was 69.3% and 74.1% in the 6M and 12M groups, respectively (p = 0.0143, HR = 0.796, 90% CI: 0.670-0.945). The 5-year OS was 83.2% and 87.6%, respectively (p = 0.0124, HR = 0.727, 90% CI: 0.575-0.919). The incidence of overall grade 3-4 adverse events was almost comparable in both groups.Although 12-month adjuvant capecitabine did not demonstrate superior DFS to that of 6-month, the observed better RFS and OS in the 12-month treatment period could be of value in selected cases." @default.
• W2919626362 created "2019-03-11" @default.
• W2919626362 creator A5001334483 @default.
• W2919626362 creator A5001994559 @default.
• W2919626362 creator A5003621363 @default.
• W2919626362 creator A5003648443 @default.
• W2919626362 creator A5004420462 @default.
• W2919626362 creator A5008803613 @default.
• W2919626362 creator A5010090426 @default.
• W2919626362 creator A5033008284 @default.
• W2919626362 creator A5033996153 @default.
• W2919626362 creator A5058441704 @default.
• W2919626362 creator A5059829141 @default.
• W2919626362 creator A5072329283 @default.
• W2919626362 creator A5073330859 @default.
• W2919626362 creator A5074557622 @default.
• W2919626362 creator A5076211862 @default.
• W2919626362 creator A5084276407 @default.
• W2919626362 creator A5086205123 @default.
• W2919626362 date "2019-03-05" @default.
• W2919626362 modified "2023-10-18" @default.
• W2919626362 title "Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study" @default.
• W2919626362 cites W1757407923 @default.
• W2919626362 cites W1905936368 @default.
• W2919626362 cites W1934256528 @default.
• W2919626362 cites W1967088757 @default.
• W2919626362 cites W2118415193 @default.
• W2919626362 cites W2118950501 @default.
• W2919626362 cites W2137408681 @default.
• W2919626362 cites W2146161922 @default.
• W2919626362 cites W2155521795 @default.
• W2919626362 cites W2161201374 @default.
• W2919626362 cites W2168600267 @default.
• W2919626362 cites W2171232394 @default.
• W2919626362 cites W2202737266 @default.
• W2919626362 cites W2225065195 @default.
• W2919626362 cites W2276054465 @default.
• W2919626362 cites W2282219011 @default.
• W2919626362 cites W2577929221 @default.
• W2919626362 cites W2586266883 @default.
• W2919626362 cites W2795004907 @default.
• W2919626362 cites W4240184954 @default.
• W2919626362 doi "https://doi.org/10.1038/s41416-019-0410-0" @default.
• W2919626362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6461756" @default.
• W2919626362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30833647" @default.
• W2919626362 hasPublicationYear "2019" @default.
• W2919626362 type Work @default.
• W2919626362 sameAs 2919626362 @default.
• W2919626362 citedByCount "17" @default.
• W2919626362 countsByYear W29196263622020 @default.
• W2919626362 countsByYear W29196263622021 @default.
• W2919626362 countsByYear W29196263622022 @default.
• W2919626362 countsByYear W29196263622023 @default.
• W2919626362 crossrefType "journal-article" @default.
• W2919626362 hasAuthorship W2919626362A5001334483 @default.
• W2919626362 hasAuthorship W2919626362A5001994559 @default.
• W2919626362 hasAuthorship W2919626362A5003621363 @default.
• W2919626362 hasAuthorship W2919626362A5003648443 @default.
• W2919626362 hasAuthorship W2919626362A5004420462 @default.
• W2919626362 hasAuthorship W2919626362A5008803613 @default.
• W2919626362 hasAuthorship W2919626362A5010090426 @default.
• W2919626362 hasAuthorship W2919626362A5033008284 @default.
• W2919626362 hasAuthorship W2919626362A5033996153 @default.
• W2919626362 hasAuthorship W2919626362A5058441704 @default.
• W2919626362 hasAuthorship W2919626362A5059829141 @default.
• W2919626362 hasAuthorship W2919626362A5072329283 @default.
• W2919626362 hasAuthorship W2919626362A5073330859 @default.
• W2919626362 hasAuthorship W2919626362A5074557622 @default.
• W2919626362 hasAuthorship W2919626362A5076211862 @default.
• W2919626362 hasAuthorship W2919626362A5084276407 @default.
• W2919626362 hasAuthorship W2919626362A5086205123 @default.
• W2919626362 hasBestOaLocation W29196263621 @default.
• W2919626362 hasConcept C120665830 @default.
• W2919626362 hasConcept C121332964 @default.
• W2919626362 hasConcept C121608353 @default.
• W2919626362 hasConcept C126322002 @default.
• W2919626362 hasConcept C141071460 @default.
• W2919626362 hasConcept C146357865 @default.
• W2919626362 hasConcept C151730666 @default.
• W2919626362 hasConcept C168563851 @default.
• W2919626362 hasConcept C197934379 @default.
• W2919626362 hasConcept C203092338 @default.
• W2919626362 hasConcept C2776694085 @default.
• W2919626362 hasConcept C2777863537 @default.
• W2919626362 hasConcept C2777909004 @default.
• W2919626362 hasConcept C2778336483 @default.
• W2919626362 hasConcept C2780456651 @default.
• W2919626362 hasConcept C2780962732 @default.
• W2919626362 hasConcept C2781413609 @default.
• W2919626362 hasConcept C526805850 @default.
• W2919626362 hasConcept C61511704 @default.
• W2919626362 hasConcept C71924100 @default.
• W2919626362 hasConcept C86803240 @default.
• W2919626362 hasConcept C90924648 @default.
• W2919626362 hasConceptScore W2919626362C120665830 @default.
• W2919626362 hasConceptScore W2919626362C121332964 @default.
• W2919626362 hasConceptScore W2919626362C121608353 @default.
• W2919626362 hasConceptScore W2919626362C126322002 @default.

• next